Vtv Therapeutics Inc., of High Point, N.C., reported results from the phase Ib portion of Simplici-T1, a phase Ib/II trial testing TTP-399 in patients with type 1 diabetes. Over one week of daily dosing in five patients, the drug was well-tolerated and improved or maintained glycemic control while reducing or simplifying patients' insulin regimen.